EUVIMEDDescobrir EUVIMED
Crossref

Novel cannabinoid receptor 1 inverse agonist CRB ‐913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet‐induced obesity mouse model

Marshall Morningstar iD, Andrew Kolodziej, Suzie Ferreira, Tracy Blumen, Rachael Brake, Yuval Cohen

Obesity · 2023

DOI: 10.1002/oby.23902 ↗

At a glance

Journal article in Obesity, 2023. Written by Marshall Morningstar and 5 co-authors. Institution: Corbus Pharmaceuticals, Norwood, Massachusetts, USA. Major MEDLINE topics: Drug Inverse Agonism, Liraglutide. Cited 27 times so far (Crossref); 44 references.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Objective

Incretin receptor agonists are now standard of care in treating obesity. Their efficacy and tolerability might be further improved by combining them with compounds that offer orthogonal mechanisms of action. The cannabinoid type 1 receptor (CB1R) is a clinically validated therapeutic target in obesity, and several experimental CB1R inverse agonists have been shown to induce weight loss.

Methods

This study characterizes a novel CB1R inverse agonist (CRB‐913) with similar preclinical potency to rimonabant but markedly reduced brain penetration. CRB‐913 was tested as monotherapy and in combination with tirzepatide, semaglutide, or liraglutide in the diet‐induced obesity (DIO) mouse model for body weight reduction.

Results

CRB‐913 demonstrated enhanced plasma exposure (3.8‐fold larger area under the curve last ) and reduced brain levels (9.5‐fold lower area under the curve last ) than rimonabant. CRB‐913 monotherapy yielded a dose‐dependent decrease in body weight in DIO mice reaching −22% within 18 days. In further DIO studies in combination with tirzepatide, semaglutide, or liraglutide, CRB‐913 (2.5 mg/kg) resulted in −32.6%, −28.8%, and −16.8% decreases in body weight on Day 18, respectively, with concomitant improvements in body fat content, liver triglycerides, and liver fat deposits.

Conclusions

CRB‐913 in combination with incretin analogues could deliver meaningful improvements over current standards of care for obesity and related conditions.

Subjects

MeSH terms (MEDLINE)

Drug Inverse AgonismLiraglutideMiceAnimalsRimonabantIncretinsObesityBody WeightDietWeight LossReceptors, CannabinoidTirzepatideSemaglutide

Substances

RimonabantLiraglutideIncretinsReceptors, CannabinoidTirzepatideSemaglutide

Authors and institutions

  • Corbus Pharmaceuticals, Norwood, Massachusetts, USA.

ORCID profiles: Marshall Morningstar

Cite

APA

Morningstar, M., Kolodziej, A., Ferreira, S., Blumen, T., Brake, R., & Cohen, Y. (2023). Novel cannabinoid receptor 1 inverse agonist CRB ‐913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet‐induced obesity mouse model. Obesity. https://doi.org/10.1002/oby.23902

Vancouver

Morningstar M, Kolodziej A, Ferreira S, Blumen T, Brake R, Cohen Y. Novel cannabinoid receptor 1 inverse agonist CRB ‐913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet‐induced obesity mouse model. Obesity. 2023. doi:10.1002/oby.23902

BibTeX
@article{Morningstar2023,
  author = {Morningstar, Marshall and Kolodziej, Andrew and Ferreira, Suzie and Blumen, Tracy and Brake, Rachael and Cohen, Yuval},
  title = {Novel cannabinoid receptor 1 inverse agonist CRB ‐913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet‐induced obesity mouse model},
  journal = {Obesity},
  year = {2023},
  doi = {10.1002/oby.23902}
}
Start for free →